Literature DB >> 18056603

Vaccination against human papillomavirus.

Alex Ferenczy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18056603      PMCID： PMC2096480          DOI： 10.1503/cmaj.1070123

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  5 in total

1.  Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.

Authors:  Diane M Harper; Eduardo L Franco; Cosette M Wheeler; Anna-Barbara Moscicki; Barbara Romanowski; Cecilia M Roteli-Martins; David Jenkins; Anne Schuind; Sue Ann Costa Clemens; Gary Dubin
Journal:  Lancet       Date:  2006-04-15       Impact factor: 79.321

2.  Human papillomavirus, vaccines and women's health: questions and cautions.

Authors:  Abby Lippman; Ryan Melnychuk; Carolyn Shimmin; Madeline Boscoe
Journal:  CMAJ       Date:  2007-08-01       Impact factor: 8.262

3.  Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.

Authors:  Suzanne M Garland; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Diane M Harper; Sepp Leodolter; Grace W K Tang; Daron G Ferris; Marc Steben; Janine Bryan; Frank J Taddeo; Radha Railkar; Mark T Esser; Heather L Sings; Micki Nelson; John Boslego; Carlos Sattler; Eliav Barr; Laura A Koutsky
Journal:  N Engl J Med       Date:  2007-05-10       Impact factor: 91.245

4.  Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials.

Authors:  Kevin A Ault
Journal:  Lancet       Date:  2007-06-02       Impact factor: 79.321

5.  High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up.

Authors:  L L Villa; R L R Costa; C A Petta; R P Andrade; J Paavonen; O-E Iversen; S-E Olsson; J Høye; M Steinwall; G Riis-Johannessen; A Andersson-Ellstrom; K Elfgren; G von Krogh; M Lehtinen; C Malm; G M Tamms; K Giacoletti; L Lupinacci; R Railkar; F J Taddeo; J Bryan; M T Esser; H L Sings; A J Saah; E Barr
Journal:  Br J Cancer       Date:  2006-11-21       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.